Meriofert (Follicle-Stimulating Hormone, Luteinising Hormone)

The two hormones bind to specific receptors on ovarian cells, activating signaling pathways that increase estrogen production, promote the growth and maturation of ovarian follicles, and ultimately trigger ovulation. This restores the natural hormonal cascade needed for successful conception.

Dosing of Meriofert is individualized. The prescribing physician determines the amount and frequency based on the patient’s ovarian response, body weight, and treatment protocol, often adjusting the dose after monitoring ultrasound and hormone levels.

Meriofert is not intended for use during an established pregnancy, and its safety in breastfeeding has not been established. Women should be confirmed non‑pregnant before starting therapy, and breastfeeding decisions should be made in consultation with a healthcare professional.

To order Meriofert, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

Meriofert combines both FSH and LH activity, whereas many alternatives provide only recombinant FSH. The dual action can more closely mimic natural ovarian stimulation, potentially reducing the need for additional LH supplementation in certain protocols.

Meriofert should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. Keep it in the original packaging until use to maintain stability.

Meriofert is given by subcutaneous injection, typically into the abdominal wall or thigh. The vial is reconstituted with the appropriate diluent if required, and the dose is administered using a sterile syringe according to the prescriber’s instructions.

The most serious risks include severe ovarian hyperstimulation syndrome, which can cause abdominal pain, fluid accumulation, and electrolyte imbalance, as well as the possibility of multiple pregnancy and rare thromboembolic events. Prompt medical attention is required if any of these occur.

Meriofert is contraindicated in women who are already pregnant, have known hypersensitivity to the active ingredients, have active ovarian cysts, or have uncontrolled thyroid disease. It should also be used with caution in patients with a history of thromboembolic disorders.